FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
|Articles|June 1, 2009
- Psychiatric Times Vol 26 No 6
- Volume 26
- Issue 6
The Insanity Offense
Author(s)Kenneth J. Weiss, MD
Make no mistake: Dr Torrey is on the side of the patient. He is enraged by the plight of the seriously mentally ill in the postinstitutional era, and he takes aim at a troika of villains-deinstitutionalization, the civil liberties bar, and the antipsychiatry movement. These 20th-century forces have conspired to relegate citizens with mental illness to a deplorable state of neglect that puts us all at risk. The Insanity Offense threads a needle of making us fear the violent mentally ill without stigmatizing them as a group.
Advertisement
Array
Articles in this issue
over 17 years ago
Fatih Akin’s Head Onover 17 years ago
Psychotherapy Supervision (2nd ed)over 17 years ago
DSM-V: Applying the Medical Modelover 17 years ago
Clinical Reflections: The Journey Out of Madnessover 17 years ago
Troubled Watersover 17 years ago
From Pedophilia to AddictionAdvertisement
Related to this article
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
4
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
5